SAFC invests in commercial-scale ADC conjugation manufacturing and services
Expands SafeBridge certified HPAPI manufacturing and storage capacity
Sigma-Aldrich Corporation's custom manufacturing services business unit, SAFC Commercial, is expanding two of its manufacturing facilities in the US. As a direct result of increasing customer demand, it is investing in commercial-scale manufacturing capacity for antibody drug conjugates (ADCs) in St Louis, Missouri, and expanding its high-potency active pharmaceutical ingredient (HPAPI) manufacturing and storage at the Verona facility near Madison, Wisconsin.
The ADC expansion at the St Louis site is expected to be completed by mid-2015 and will feature segregated areas for high-potent solids handling, manufacturing and aseptic bulk filling of product. Batches up to 600L/3kg can be manufactured under ISO 7 classification and the facility is suitable for HPAPI containment for SafeBridge Category 4 compounds.
Additional commercial-scale manufacturing capacity has also been designed to seamlessly accommodate future growth in demand for ADC production. Online since mid-2010 and SafeBridge certified in October 2011, the Verona site was originally constructed as an add-on to the Madison facility for cGMP manufacture of late-phase and commercial HPAPIs requiring 200 to 4,000 litres capacity. By mid-2014, the site will have a new warehouse with storage capacity for raw materials, as well as three new cGMP manufacturing areas to support projects.
Two of the areas will be designated for smaller lab-scale manufacturing in the kilo range, while the other will accommodate larger-scale manufacturing up to 800 litres. The facility expansion will also provide space for growth of SAFC's product stability sample storage and testing service, as well as a process scale-up lab to support GMP production.
'These strategic investments are the result of ongoing dialogue with customers. We are directly addressing their needs for supply chain continuity when sourcing the high-quality manufacturing materials, technologies and services that drive the performance of their end products,' said Gilles Cottier, President of SAFC.
'Once complete, the St. Louis expansion will enable continuous scale-up of ADCs from preclinical to clinical phases and into commercial-scale production,' said Head of Global Strategic Marketing for Contract Manufacturing Services & Solutions at SAFC Andreas Weiler. 'ADC technologies have shown exceptional promise in targeted therapies for chronic diseases, such as cancer, so strategic investments in this facility made sense to support our customers through all phases of ADC innovation.'
'The investments at the St Louis and Verona sites are complementary and allow SAFC to offer continuity for customers' drug development and commercialisation programmes,' added Dave Bormett, Director of Operations for SAFC. 'Verona's HPAPI handling and containment standards (< 0.1µg/m3) enable the site to manufacture the high-potency toxins and linkers that the St. Louis site uses to conjugate biological molecules and develop ADCs.
'It is all a part of our drive to provide customers with complete solutions based on our expertise in niche technologies.'
